Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking & Finance Review®

Global Banking & Finance Review® - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Profile
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release
    • Awards▾
      • About the Awards
      • Awards TimeTable
      • Submit Nominations
      • Testimonials
      • Media Room
      • Award Winners
      • FAQ
    • Magazines▾
      • Global Banking & Finance Review Magazine Issue 79
      • Global Banking & Finance Review Magazine Issue 78
      • Global Banking & Finance Review Magazine Issue 77
      • Global Banking & Finance Review Magazine Issue 76
      • Global Banking & Finance Review Magazine Issue 75
      • Global Banking & Finance Review Magazine Issue 73
      • Global Banking & Finance Review Magazine Issue 71
      • Global Banking & Finance Review Magazine Issue 70
      • Global Banking & Finance Review Magazine Issue 69
      • Global Banking & Finance Review Magazine Issue 66
    Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2026 GBAF Publications Ltd - All Rights Reserved. | Sitemap | Tags | Developed By eCorpIT

    Editorial & Advertiser disclosure

    Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Home > Finance > Pfizer sells entire Haleon stake for $3.24 billion
    Finance

    Pfizer sells entire Haleon stake for $3.24 billion

    Published by Global Banking & Finance Review®

    Posted on March 19, 2025

    2 min read

    Last updated: January 24, 2026

    Pfizer sells entire Haleon stake for $3.24 billion - Finance news and analysis from Global Banking & Finance Review
    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    Quick Summary

    Pfizer sold its entire Haleon stake for $3.24 billion, with shares bought by institutional investors and Haleon. BlackRock now holds the largest stake.

    Pfizer Sells Entire Stake in Haleon for $3.24 Billion

    (Reuters) -Drugmaker Pfizer has sold its entire stake in Haleon for about 2.5 billion pounds ($3.24 billion) to institutional investors and the consumer healthcare firm at 385 pence per share, a bookrunner for the deal said on Wednesday.

    Under the deal, Sensodyne maker Haleon has agreed to buy back 44 million shares from Pfizer, currently its largest shareholder, with 618 million shares being sold to institutional investors.

    The total sale represents 7.3% of the issued share capital of Haleon, which was created by the merger of GSK and Pfizer's consumer healthcare businesses in 2019. It was spun off from the British drugmaker in 2022.

    GSK, which initially owned nearly 13% of the firm, sold its entire stake in May 2024.

    Following Pfizer's disposal, BlackRock Investment Management (UK) Ltd, a unit of BlackRock, will become Haleon's largest shareholder with a more than 5% stake, according to data compiled by LSEG.

    BofA Securities, Citigroup Global Markets Limited, and Goldman Sachs International are joint global coordinators while Barclays and Deutsche Numis are joint bookrunners for the share sale.

    Haleon, which also makes Panadol and Advil painkillers, said in February its 2025 revenue and profit growth would be weighted to the second half of the year.

    ($1 = 0.7708 pounds)

    (Reporting by Anandita Mehrotra in Bengaluru; Editing by Mrigank Dhaniwala)

    Key Takeaways

    • •Pfizer sold its entire Haleon stake for $3.24 billion.
    • •Haleon agreed to buy back 44 million shares.
    • •618 million shares sold to institutional investors.
    • •BlackRock becomes Haleon's largest shareholder.
    • •Haleon was spun off from GSK in 2022.

    Frequently Asked Questions about Pfizer sells entire Haleon stake for $3.24 billion

    1What is the main topic?

    The article discusses Pfizer's sale of its entire stake in Haleon for $3.24 billion to institutional investors and Haleon.

    2Who becomes Haleon's largest shareholder?

    After the sale, BlackRock Investment Management becomes Haleon's largest shareholder with over a 5% stake.

    3What was the price per share in the sale?

    The shares were sold at 385 pence per share.

    More from Finance

    Explore more articles in the Finance category

    Image for French miner Eramet's finance chief steps aside temporarily, days after CEO ouster
    French miner Eramet's finance chief steps aside temporarily, days after CEO ouster
    Image for Ukraine's Zelenskiy calls for faster action on air defence, repairs to grid
    Ukraine's Zelenskiy calls for faster action on air defence, repairs to grid
    Image for Goldman Sachs teams up with Anthropic to automate banking tasks with AI agents, CNBC reports
    Goldman Sachs teams up with Anthropic to automate banking tasks with AI agents, CNBC reports
    Image for Analysis-Hims' $49 weight-loss pill rattles investor case for cash-pay obesity market
    Analysis-Hims' $49 weight-loss pill rattles investor case for cash-pay obesity market
    Image for Analysis-Glencore to focus on short-term disposals as Rio deal remains elusive
    Analysis-Glencore to focus on short-term disposals as Rio deal remains elusive
    Image for Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
    Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
    Image for Big Tech's quarter in four charts: AI splurge and cloud growth
    Big Tech's quarter in four charts: AI splurge and cloud growth
    Image for EU hikes tariffs on Chinese ceramics to 79% to counter dumping 
    EU hikes tariffs on Chinese ceramics to 79% to counter dumping 
    Image for AI trade splinters as investors get more selective
    AI trade splinters as investors get more selective
    Image for EU extends tariff suspension on $109.8 billion of US imports for six months
    EU extends tariff suspension on $109.8 billion of US imports for six months
    Image for Dog food maker Ollie acquired by Spain’s Agrolimen
    Dog food maker Ollie acquired by Spain’s Agrolimen
    Image for Salzgitter to take over HKM steel joint venture, end clash with Thyssenkrupp
    Salzgitter to take over HKM steel joint venture, end clash with Thyssenkrupp
    View All Finance Posts
    Previous Finance PostVitol snaps up West Africa assets from Eni, strengthening upstream presence
    Next Finance PostTurkey detains Istanbul mayor in what opposition calls 'coup'